112 related articles for article (PubMed ID: 20683013)
1. Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer.
Hauser S; Zahalka T; Ellinger J; Fechner G; Heukamp LC; VON Ruecker A; Müller SC; Bastian PJ
Anticancer Res; 2010 Jul; 30(7):2785-9. PubMed ID: 20683013
[TBL] [Abstract][Full Text] [Related]
2. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum-circulating RNA in patients with conventional renal cell cancer.
Feng G; Li G; Gentil-Perret A; Tostain J; Genin C
Anticancer Res; 2008; 28(1A):321-6. PubMed ID: 18383864
[TBL] [Abstract][Full Text] [Related]
4. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
5. Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study.
Hauser S; Zahalka T; Fechner G; Müller SC; Ellinger J
Anticancer Res; 2013 Oct; 33(10):4651-6. PubMed ID: 24123044
[TBL] [Abstract][Full Text] [Related]
6. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker.
Ellinger J; Albers P; Müller SC; von Ruecker A; Bastian PJ
BJU Int; 2009 Jul; 104(1):48-52. PubMed ID: 19154496
[TBL] [Abstract][Full Text] [Related]
7. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
[TBL] [Abstract][Full Text] [Related]
8. Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage.
Singh KJ; Singh SK; Suri A; Vijjan V; Goswami AK; Khullar M
Indian J Cancer; 2005; 42(4):197-200. PubMed ID: 16391438
[TBL] [Abstract][Full Text] [Related]
9. DNA integrity in plasma and serum of patients with malignant and benign diseases.
Holdenrieder S; Burges A; Reich O; Spelsberg FW; Stieber P
Ann N Y Acad Sci; 2008 Aug; 1137():162-70. PubMed ID: 18837942
[TBL] [Abstract][Full Text] [Related]
10. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
11. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma.
Chang CH; Wu HC; Yen RF; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(5):2949-50. PubMed ID: 12530023
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Stenzl A; Beger G; Rinnab L; Kuczyk MA; Kuefer R
Urol Int; 2007; 79(1):41-3. PubMed ID: 17627167
[TBL] [Abstract][Full Text] [Related]
13. Prediction of breast tumor progression by integrity of free circulating DNA in serum.
Umetani N; Giuliano AE; Hiramatsu SH; Amersi F; Nakagawa T; Martino S; Hoon DS
J Clin Oncol; 2006 Sep; 24(26):4270-6. PubMed ID: 16963729
[TBL] [Abstract][Full Text] [Related]
14. Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer.
Tomita H; Ichikawa D; Ikoma D; Sai S; Tani N; Ikoma H; Fujiwara H; Kikuchi S; Okamoto K; Ochiai T; Otsuji E
Anticancer Res; 2007; 27(4C):2737-41. PubMed ID: 17695440
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity.
Ellinger J; Bastian PJ; Ellinger N; Kahl P; Perabo FG; Büttner R; Müller SC; Ruecker Av
Cancer Lett; 2008 Jun; 264(2):274-80. PubMed ID: 18329789
[TBL] [Abstract][Full Text] [Related]
16. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma.
Hauser S; Wulfken LM; Holdenrieder S; Moritz R; Ohlmann CH; Jung V; Becker F; Herrmann E; Walgenbach-Brünagel G; von Ruecker A; Müller SC; Ellinger J
Cancer Epidemiol; 2012 Aug; 36(4):391-4. PubMed ID: 22542158
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance.
Mizutani Y; Nakanishi H; Yamamoto K; Li YN; Matsubara H; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
J Clin Oncol; 2005 Jan; 23(3):448-54. PubMed ID: 15572731
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
Jacobsen J; Rasmuson T; Grankvist K; Ljungberg B
J Urol; 2000 Jan; 163(1):343-7. PubMed ID: 10604387
[TBL] [Abstract][Full Text] [Related]
20. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]